Rock Point Advisors’s Biogen BIIB Stock Holding History

Rock Point Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$398K	Hold	1,840	–	–	0.1%	81
2026 Q1	$337K	Hold	1,840	–	–	0.09%	87
2025 Q4	$324K	Hold	1,840	–	–	0.08%	89
2025 Q3	$258K	Hold	1,840	–	–	0.07%	98
2025 Q2	$231K	Hold	1,840	–	–	0.07%	99
2025 Q1	$252K	Hold	1,840	–	–	0.08%	91
2024 Q4	$281K	Hold	1,840	–	–	0.08%	86
2024 Q3	$357K	Hold	1,840	–	–	0.1%	82
2024 Q2	$427K	Hold	1,840	–	–	0.13%	73
2024 Q1	$397K	Hold	1,840	–	–	0.12%	73
2023 Q4	$476K	Hold	1,840	–	–	0.14%	63
2023 Q3	$473K	Buy	+1,840	New	+$492K	0.16%	67

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rock Point Advisors's BIIB Position: Q2 2026 in Review

Rock Point Advisors held its Biogen (BIIB) position steady in Q2 2026 at 1,840 shares worth $398K. The position accounts for 0.1% of the portfolio, ranked #81.

Rock Point Advisors first reported a position in BIIB in Q3 2023 and has held it in 12 quarters since. The position peaked at $476K in Q4 2023. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Rock Point Advisors held 1,840 shares of Biogen worth $398K as of Q2 2026.
Rock Point Advisors left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.1% of Rock Point Advisors's portfolio in Q2 2026, its #81 holding.
Rock Point Advisors first reported a position in Biogen in Q3 2023 and has held it in 12 quarters since.
Rock Point Advisors's Biogen position peaked at $476K in Q4 2023.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Rock Point Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.